Sodium Phenylbutyrate Ameliorates Ovariectomy-Induced Bone Loss in Rats

Area of Science:

• Biomedical Science
• Pharmacology
• Bone Biology

Background:

• Estrogen deficiency post-menopause accelerates bone loss via oxidative stress and inflammatory cytokines.
• Postmenopausal osteoporosis is a significant health concern linked to hormonal changes.
• The therapeutic potential of histone deacetylase inhibitors like Sodium Phenylbutyrate (SPB) for osteoporosis is largely unexplored.

Purpose of the Study:

• To investigate the effects of Sodium Phenylbutyrate (SPB) on bone loss in an ovariectomized (OVX) rat model.
• To evaluate SPB's impact on oxidative stress, inflammation, and bone resorption markers.
• To assess SPB's efficacy in improving bone mineral density and histomorphometric parameters.

Main Methods:

• Thirty female Wistar rats were divided into control, OVX, and OVX+SPB groups.
• Bone mineral density (BMD), histomorphometry, and bone marrow biomarkers were assessed after 12 weeks.
• Evaluated biomarkers included MDA, TNF-α, IL-6, RANKL, and plasma Cathepsin K.

Main Results:

• OVX rats exhibited significant trabecular deterioration and decreased BMD, alongside elevated MDA, TNF-α, IL-6, RANKL, and Cathepsin K.
• SPB treatment significantly improved trabecular bone structure and increased femoral and lumbar BMD in OVX rats.
• SPB administration markedly reduced levels of oxidative stress markers, inflammatory cytokines, and osteoclast activity indicators.

Conclusions:

• Sodium Phenylbutyrate (SPB) effectively mitigates ovariectomy-induced bone loss by reducing oxidative stress, inflammation, and osteoclast activity.
• SPB demonstrates significant improvements in biochemical, structural, and histomorphometric parameters in estrogen-deficient rats.
• SPB is a potential cost-effective candidate for repurposing in postmenopausal osteoporosis, meriting further clinical investigation.